Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index; 12 of the 16 sources its claims cite were checked for support.
Abstract
BACKGROUND: Vaccines are needed to prevent coronavirus disease 2019 (Covid-19) and to protect persons who are at high risk for complications. The mRNA-1273 vaccine is a lipid nanoparticle-encapsulated mRNA-based vaccine that encodes the prefusion stabilized full-length spike protein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes Covid-19. METHODS: This phase 3 randomized, observer-blinded, placebo-controlled trial was conducted at 99 centers across the United States. Persons at high risk for SARS-CoV-2 infection or its complications were randomly assigned in a 1:1 ratio to receive two intramuscular injections of mRNA-1273 (100 μg) or placebo 28 days apart. The primary end point was prevention of Covid-19 illness with onset at least 14 days after the second injection in participants who had not previously been infected with SARS-CoV-2. RESULTS: The trial enrolled 30,420 volunteers who were randomly assigned in a 1:1 ratio to receive either vaccine or placebo (15,210 participants in each group). More than 96% of participants received both injections, and 2.2% had evidence (serologic, virologic, or both) of SARS-CoV-2 infection at baseline. Symptomatic Covid-19 illness was confirmed in 185 participants in the placebo group (56.5 per 1000 person-years; 95% confidence interval [CI], 48.7 to 65.3) and in 11 participants in the mRNA-1273 group (3.3 per 1000 person-years; 95% CI, 1.7 to 6.0); vaccine efficacy was 94.1% (95% CI, 89.3 to 96.8%; P<0.001). Efficacy was similar across key secondary analyses, including assessment 14 days after the first dose, analyses that included participants who had evidence of SARS-CoV-2 infection at baseline, and analyses in participants 65 years of age or older. Severe Covid-19 occurred in 30 participants, with one fatality; all 30 were in the placebo group. Moderate, transient reactogenicity after vaccination occurred more frequently in the mRNA-1273 group. Serious adverse events were rare, and the incidence was similar in the two groups. CONCLUSIONS: The mRNA-1273 vaccine showed 94.1% efficacy at preventing Covid-19 illness, including severe disease. Aside from transient local and systemic reactions, no safety concerns were identified. (Funded by the Biomedical Advanced Research and Development Authority and the National Institute of Allergy and Infectious Diseases; COVE ClinicalTrials.gov number, NCT04470427.).
Overview
CoChat Summary
TL;DR
In a phase 3 U.S. trial, mRNA-1273 (100 μg given as two doses 28 days apart) prevented symptomatic Covid-19 with 94.1% efficacy and showed no safety concerns beyond transient reactogenicity. Severe Covid-19 occurred in 30 participants, all in the placebo group.
Key findings
- Among 30,420 randomized participants (15,210 per group), the primary per-protocol analysis found symptomatic Covid-19 in 11 mRNA-1273 recipients vs. 185 placebo recipients (3.3 vs. 56.5 per 1000 person-years), for vaccine efficacy of 94.1% (95% CI, 89.3 to 96.8; P<0.001).
- Severe Covid-19 occurred in 30 participants, all in the placebo group (vaccine efficacy 100%; 95% CI could not be estimated to 1.0), including one Covid-19–related death.
- Solicited local adverse events were more frequent with mRNA-1273 after dose 1 (84.2% vs. 19.8%) and dose 2 (88.6% vs. 18.8%); solicited systemic events were also more frequent after dose 1 (54.9% vs. 42.2%) and dose 2 (79.4% vs. 36.5%). Serious adverse events were similar (0.6% in both groups).
- Efficacy was similar across subgroups, including 95.6% among participants 18 to <65 years, 86.4% among those ≥65 years, and 97.5% in communities of color.
Methods
- Phase 3 randomized, observer-blinded, placebo-controlled trial conducted at 99 U.S. centers; adults at high risk for SARS-CoV-2 infection or severe Covid-19 were assigned 1:1 to receive two intramuscular injections of mRNA-1273 (100 μg) or placebo 28 days apart.
- The primary end point was prevention of symptomatic Covid-19 with onset at least 14 days after the second injection in per-protocol participants who were seronegative at baseline; cases were adjudicated, and vaccine efficacy was defined as 1 minus the hazard ratio (mRNA-1273 vs. placebo) using a stratified Cox proportional hazards model.
- Safety was assessed in all participants who received at least one injection, including solicited local and systemic adverse events for 7 days after each injection, unsolicited adverse events for 28 days, and serious/medically attended events through day 759.
Limitations
- Stated: short duration of safety and efficacy follow-up (median 64 days after the second dose; 2-year follow-up planned); no identified correlate of protection; insufficient data to assess asymptomatic infection; limited cases in older adults, racial/ethnic minorities, and previously infected persons; pregnant women and children were excluded.
- Stated: the trial was not designed to evaluate single-dose efficacy; rare adverse events are hard to detect given sample size; long-term risk of enhanced respiratory disease after exposure remains unknown.
- Evident: the primary analysis reflects only short-term follow-up, so durability of protection is unknown; subgroup estimates have wide confidence intervals (e.g., ≥65 years: 86.4%, 95% CI 61.4 to 95.2).
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 0 Not valid · 3 Not checked · 79 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“The efficacy of mRNA-1273 is in line with that of the recently reported BNT162b2 mRNA vaccine. 16”
What the sources say
- Supportedcites [16] 16. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 Covid-19 vaccine. N Engl J Med 2020; 383: 2603-15. source
The Abstract Results report that BNT162b2 was 95% effective in preventing Covid-19, and the Discussion likewise describes 95% efficacy after two doses. The comparison with mRNA-1273 is the citing authors’ own framing; this source supplies the BNT162b2 efficacy result. (LLM, conf=0.91)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The reactogenicity associated with immunization with mRNA-1273 in this trial is similar to that in the phase 1 data reported previously. 1,4”
What the sources say
- Supportedcites [1] 1. Jackson LA, Anderson EJ, Rouphael NG, et al. An mRNA vaccine against SARS-CoV-2 - preliminary report. N Engl J Med 2020; 383: 1920-31. source
The Methods identify this as a phase 1 trial of mRNA-1273 that evaluated reactogenicity. The Results (Vaccine Safety; page unavailable) report its reactogenicity findings, so it supports the citation’s reference to previously reported phase 1 data. (LLM, conf=0.88)
- Supportedcites [4] 4. Anderson EJ, Rouphael NG, Widge AT, et al. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. N Engl J Med 2020; 383: 2427-38. source
The Discussion states that the authors observed no systematic differences in reactogenicity between the older participants in this study and younger mRNA-1273 recipients reported previously. It cautions that the small groups do not permit meaningful formal statistical comparisons, but the citing sentence makes only a qualitative comparison. (LLM, conf=0.93)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In the overall population, the incidence of treatment-related severe adverse events was higher in the mRNA-1273 group (71 participants [0.5%]) than in the placebo group (28 participants [0.2%]) (Tables S8 and S15).”
plainstates an associationn = 71- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Adverse events that were deemed by the trial team to be related to the vaccine or placebo were reported among 4.5% of participants in the placebo group and 8.2% in the mRNA-1273 group.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The relative incidence of these adverse events according to vaccine group was not affected by age.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
35 more claims
Create a free account to see all 88 claims and every source verdict.
- It may state two separate claims as one. 39
- Probably not a substantial claim. 21
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [44]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [31]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Currently licensed vaccines have shown efficacies of up to 95% in preventing laboratory-confirmed infection over the first few months after vaccination61–63”
From Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection (2021) · cites this paper as [62]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The two mRNA vaccines approved to date show efficacy even after only one dose, when non-NAbs and moderate T helper 1 cell responses are detectable, but almost no NAbs.”
From Immunological mechanisms of vaccine-induced protection against COVID-19 in humans (2021) · cites this paper as [82]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Robust CD4+ and CD8+ T cell memory is induced after COVID-19,22,39, 40, 41 and multiple COVID-19 vaccines elicit CD4+ and CD8+ T cell responses.26,42, 43, 44, 45”
From Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals (2021) · cites this paper as [44]
Experimental — accuracy not yet measured
43 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592
Voysey, M., Clemens, S. A. C., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., Angus, B., Baillie, V. L., Barnabas, S. L., Bhorat, Q. E., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32661-1 · Cited by 4,616
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,406
Self-citationRNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationFolegatti, P. M., Ewer, K. J., Aley, P. K., Angus, B., Becker, S., Belij-Rammerstorfer, S., Bellamy, D., Bibi, S., Bittaye, M., Clutterbuck, E. A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31604-4 · Cited by 2,419
The COVID-19 vaccine development landscape
Thanh Le, T., Andreadakis, Z., Kumar, A., Gómez Román, R., Tollefsen, S., Saville, M., & Mayhew, S. (2020) · Nature Reviews Drug Discovery · doi:10.1038/d41573-020-00073-5 · Cited by 1,954
Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis
Osterholm, M. T., Kelley, N. S., Sommer, A., & Belongia, E. A. (2012) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70295-x · Cited by 1,789
SARS-CoV-2 mRNA Vaccine Design Enabled by Prototype Pathogen Preparedness
Corbett, K. S., Edwards, D. K., Leist, S. R., Abiona, O. M., Boyoglu-Barnum, S., Gillespie, R. A., Himansu, S., Schäfer, A., Ziwawo, C. T., DiPiazza, A. T., et al. (2020) · Nature · doi:10.1038/s41586-020-2622-0 · Cited by 1,615
Self-citationDeveloping Covid-19 Vaccines at Pandemic Speed
Lurie, N., Saville, M., Hatchett, R., & Halton, J. (2020) · New England Journal of Medicine · doi:10.1056/nejmp2005630 · Cited by 1,557
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
Anderson, E. J., Rouphael, N. G., Widge, A. T., Jackson, L. A., Roberts, P. C., Makhene, M., Chappell, J. D., Denison, M. R., Stevens, L. J., Pruijssers, A. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2028436 · Cited by 1,523
Self-citation
Cited by
Items 2,201–2,300 of 10,906
Delayed systemic urticarial reactions following mRNA COVID-19 vaccination
Pitlick, M. M., Joshi, A. Y., Gonzalez‐Estrada, A., & Chiarella, S. E. (2022) · Allergy and Asthma Proceedings · doi:10.2500/aap.2022.43.210101 · Cited by 35
Design, development and clinical translation of CriPec®-based core-crosslinked polymeric micelles
Rijcken, C. J. F., Lorenzi, F. D., Biancacci, I., Hanssen, R., Thewissen, M. M., Hu, Q., Atrafi, F., Liskamp, R. M. J., Mathijssen, R. H. J., Miedema, I. H. C., et al. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114613 · Cited by 39
BNT162b2 vaccine uptake and effectiveness in UK healthcare workers – a single centre cohort study
Azamgarhi, T., Hodgkinson, M., Shah, A., Skinner, J. A., Hauptmannova, I., Briggs, T. W. R., & Warren, S. (2021) · Nature Communications · doi:10.1038/s41467-021-23927-x · Cited by 41
Cione, E., Cannataro, R., Gallelli, L., Sarro, G. D., & Caroleo, M. C. (2021) · Pharmaceuticals · doi:10.3390/ph14121257 · Cited by 39
Hielscher, F., Schmidt, T., Klemis, V., Wilhelm, A., Marx, S., Abu‐Omar, A., Ziegler, L., Guckelmus, C., Urschel, R., Sester, U., et al. (2022) · Journal of Clinical Virology · doi:10.1016/j.jcv.2022.105321 · Cited by 36
Balcells, M. E., Corre, N. L., Durán, J., Ceballos, M. E., Vizcaya, C., Mondaca, S., Dib, M., Ricardo Rabagliati, B., Mauricio Sarmiento, M., Burgos, P. I., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac167 · Cited by 46
Systematic modulation of the lipid composition enables the tuning of liposome cellular uptake
Mateos‐Maroto, A., Gai, M., Brückner, M., Marques, R. D. C., Harley, I., Simon, J., Mailänder, V., Morsbach, S., & Landfester, K. (2023) · Acta Biomaterialia · doi:10.1016/j.actbio.2022.12.058 · Cited by 38
Synthetic circRNA therapeutics: innovations, strategies, and future horizons
Cai, J., Qiu, Z., Cho, W. C. S., Liu, Z., Chen, S., Li, H., Chen, K., Li, Y., Zuo, C., & Qiu, M. (2024) · MedComm · doi:10.1002/mco2.720 · Cited by 45
Tré‐Hardy, M., Cupaiolo, R., Wilmet, A., Beukinga, I., & Blairon, L. (2021) · Journal of Infection · doi:10.1016/j.jinf.2021.06.017 · Cited by 33
Influenza Viruses: Innate Immunity and mRNA Vaccines
Lee, S., & Ryu, J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.710647 · Cited by 39
An antibody targeting the N-terminal domain of SARS-CoV-2 disrupts the spike trimer
Suryadevara, N., Shiakolas, A. R., VanBlargan, L. A., Binshtein, E., Chen, R. E., Case, J. B., Kramer, K. J., Armstrong, E., Myers, L., Trivette, A., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci159062 · Cited by 32
Ci, L., Hard, M., Zhang, H., Gandham, S. K., Hua, S. S., Wickwire, J., Wehrman, T., Slauter, R., Auerbach, A. D., Kenney, M., et al. (2023) · Drug Metabolism and Disposition · doi:10.1124/dmd.122.000980 · Cited by 41
Rhabdomyolysis Secondary to COVID-19 Vaccination
Mack, M., Nichols, L., & Guerrero, D. M. (2021) · Cureus · doi:10.7759/cureus.15004 · Cited by 37
Nesterenko, P. A., McLaughlin, J., Tsai, B. L., Sojo, G. B., Cheng, D., Zhao, D. Y., Mao, Z., Bangayan, N. J., Obusan, M. B., Su, Y., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.110167 · Cited by 36
Savva, D., Battineni, G., Amenta, F., & Nittari, G. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.09.066 · Cited by 41
Optimization of ionizable lipids for aerosolizable mRNA lipid nanoparticles
Lewis, M. M., Soto, M. R., Maier, E. Y., Wulfe, S., Bakheet, S., Obregon, H., & Ghosh, D. (2023) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10580 · Cited by 43
Cutaneous reactions to COVID‐19 vaccine at the dermatology primary care
Burlando, M., Herzum, A., Micalizzi, C., Cozzani, E., & Parodi, A. (2021) · Immunity Inflammation and Disease · doi:10.1002/iid3.568 · Cited by 34
Acute Myocarditis Following mRNA-1273 SARS-CoV-2 Vaccination
Williams, C., Choi, J.-I., Hosseini, F., et al. (2021) · CJC Open · doi:10.1016/j.cjco.2021.07.008 · Cited by 35
Acute myocarditis caused by COVID-19 disease and following COVID-19 vaccination
Kornowski, R., & Witberg, G. (2022) · Open Heart · doi:10.1136/openhrt-2021-001957 · Cited by 37
Efficacy, Immunogenicity, and Safety of Modified mRNA Influenza Vaccine
Fitzpatrick, D., McVinnie, D. S., Jackson, L. A., Crowther, G., Geevarughese, A., Cannon, K. D., Garcia, L. M., Puebla, Y. P., Yi, Z., Cunliffe, L., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2416779 · Cited by 54
Mair, M. J., Berger, J. M., Mitterer, M., Gansterer, M., Bathke, A. C., Trutschnig, W., Berghoff, A. S., Perkmann, T., Haslacher, H., Lamm, W. W., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.01.019 · Cited by 37
The Repurposed Drugs Suramin and Quinacrine Cooperatively Inhibit SARS-CoV-2 3CLpro In Vitro
Eberle, R. J., Olivier, D. S., do Amaral, M. S., Gering, I., Willbold, D., Arni, R. K., & Coronado, M. A. (2021) · Viruses · doi:10.3390/v13050873 · Cited by 38
Advancements in monkeypox vaccines development: a critical review of emerging technologies
Garcia-Atutxa, I., Mondragón‐Terán, P., Saquero, A. H., & Villanueva‐Flores, F. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1456060 · Cited by 50
Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar
(2022) · doi:10.1101/2022.03.13.22272308 · Cited by 228
Effectiveness of the 2023–2024 Formulation of the COVID-19 Messenger RNA Vaccine
Shrestha, N. K. M., Burke, P. C., Nowacki, A. S., & Gordon, S. M. (2024) · Clinical Infectious Diseases · doi:10.1093/cid/ciae132 · Cited by 33
Intestinal Damage in COVID-19: SARS-CoV-2 Infection and Intestinal Thrombosis
Wu, X., Jing, H., Wang, C., Wang, Y., Zuo, N., Jiang, T., Novakovic, V. A., & Shi, J. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.860931 · Cited by 37
Clinically Significant COVID-19 Following SARS-CoV-2 Vaccination in Kidney Transplant Recipients
Tsapepas, D. S., Paget, K., Mohan, S., Cohen, D. J., & Husain, S. (2021) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2021.05.004 · Cited by 36
Implications of inflammatory states on dysfunctional immune responses in aging and obesity
Thomas, A. L., Alarcon, P. C., Divanovic, S., Chougnet, C. A., Hildeman, D. A., & Moreno-Fernandez, M. E. (2021) · Frontiers in Aging · doi:10.3389/fragi.2021.732414 · Cited by 35
Pulmonary delivery of mucosal nanovaccines
Tang, W., Zhang, Y., & Zhu, G. (2022) · Nanoscale · doi:10.1039/d1nr06512b · Cited by 42
Janus kinase signaling as risk factor and therapeutic target for severe SARS‐CoV‐2 infection
Solimani, F., Meier, K., & Ghoreschi, K. (2021) · European Journal of Immunology · doi:10.1002/eji.202149173 · Cited by 38
Chen, Z., Kelly, K., Cheng, H., Dong, X., Hedger, A. K., Li, L., Sontheimer, E. J., & Watts, J. K. (2023) · GEN Biotechnology · doi:10.1089/genbio.2023.0045 · Cited by 41
Seasonal quadrivalent mRNA vaccine prevents and mitigates influenza infection
Kackos, C. M., DeBeauchamp, J., Davitt, C. J. H., Lonzarić, J., Sealy, R. E., Hurwitz, J. L., Samsa, M. M., & Webby, R. J. (2023) · npj Vaccines · doi:10.1038/s41541-023-00752-5 · Cited by 40
Katz, J. D., Bouley, A. J., Jungquist, R. M., Douglas, E. A., O'Shea, I. L., & Lathi, E. S. (2021) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2021.103382 · Cited by 38
Effectiveness estimates of three COVID-19 vaccines based on observational data from Puerto Rico
Robles-Fontán, M. M., Nieves, E. G., Cardona-Gerena, I., & Irizarry, R. A. (2022) · The Lancet Regional Health - Americas · doi:10.1016/j.lana.2022.100212 · Cited by 35
Desai, A. P., Desai, A. P., & Loomis, G. J. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.06.058 · Cited by 34
Wang, X., Cottrell, C. A., Hu, X., Ray, R., Bottermann, M., Villavicencio, P. M., Yan, Y., Xie, Z., Warner, J. E., Ellis-Pugh, J. R., et al. (2024) · Science Immunology · doi:10.1126/sciimmunol.adn0622 · Cited by 35
Barbeau, D. J., Martin, J. M., Carney, E., Dougherty, E., Doyle, J., Dermody, T. S., Hoberman, A., Williams, J. V., Michaels, M. G., Alcorn, J. F., et al. (2022) · npj Vaccines · doi:10.1038/s41541-022-00504-x · Cited by 45
Li, H., Guo, L., Zheng, H., Li, J., Zhao, X., Li, J., Liang, Y., Yang, F., Zhao, Y., Yang, J., et al. (2021) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.1c00208 · Cited by 33
Sezgin, D., Dost, A., & Esin, M. (2021) · International Nursing Review · doi:10.1111/inr.12740 · Cited by 54
Eslami, M., Dowlat, B. F., Yaghmayee, S., Habibian, A., Keshavarzi, S., Oksenych, V., & Naderian, R. (2025) · Vaccines · doi:10.3390/vaccines13060588 · Cited by 54
Prediction and Evolution of the Molecular Fitness of SARS-CoV-2 Variants: Introducing SpikePro
Pucci, F., & Rooman, M. J. (2021) · Viruses · doi:10.3390/v13050935 · Cited by 35
COVID-19 vaccines and thrombosis with thrombocytopenia syndrome
Lai, C., Ko, W., Chen, C., Chen, P.-Y., Huang, Y., Lee, P., & Hsueh, P. (2021) · Expert Review of Vaccines · doi:10.1080/14760584.2021.1949294 · Cited by 42
A Meta-Analysis on the Safety and Immunogenicity of Covid-19 Vaccines
Ashmawy, R., Hamdy, N. A., Elhadi, Y. A. M., Alqutub, S. T., Esmail, O. F., Abdou, M. S. M., Reyad, O. A., El-Ganainy, S. O., Gad, B. K., El-Deen, A. E.-S. N., et al. (2022) · Journal of Primary Care & Community Health · doi:10.1177/21501319221089255 · Cited by 38
Kamanzi, A., Zhang, Y., Gu, Y., Liu, F., Berti, R., Wang, B. L., Saadati, F., Ciufolini, M. A., Kulkarni, J. A., Cullis, P. R., et al. (2024) · ACS Nano · doi:10.1021/acsnano.3c12981 · Cited by 37
The risk of miscarriage following COVID-19 vaccination: a systematic review and meta-analysis
Rimmer, M. P., Teh, J. J., Mackenzie, S. C., & Wattar, B. H. A. (2023) · Human Reproduction · doi:10.1093/humrep/dead036 · Cited by 38
Chen, J., Cai, Y., Chen, Y., Williams, A. P., Gao, Y., & Zeng, J. (2021) · Vaccines · doi:10.3390/vaccines9080939 · Cited by 35
Koh, J. S., Hoe, R. H. M., Yong, M. H., Chiew, H. J., Goh, Y., Yong, K. P., Tu, T. M., Chan, D. W. S., Tan, B. Y., Yeo, L. L. L., et al. (2021) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2021.120030 · Cited by 40
Ioannou, G. N., Green, P. K., Fan, V. S., et al. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.4347 · Cited by 35
Lin, W.-Z. S., Bostic, W. K. V., & Malmstadt, N. (2023) · Lab on a Chip · doi:10.1039/d3lc00520h · Cited by 36
VLP-Based COVID-19 Vaccines: An Adaptable Technology against the Threat of New Variants
Prates-Syed, W. A., Chaves, L. C. S., Crema, K. P., Vuitika, L., Lira, A. A. D. L., Côrtes, N., Kersten, V., Guimarães, F. E. G., Sadraeian, M., da Silva, F. L. B., et al. (2021) · Vaccines · doi:10.3390/vaccines9121409 · Cited by 39
Pajón, R., Paila, Y. D., Girard, B., Dixon, G., Kacena, K. A., Baden, L. R., Sahly, H. M. E., Essink, B. J., Mullane, K. M., Frank, I., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01679-5 · Cited by 36
Self-citationNanoformulations targeting immune cells for cancer therapy: mRNA therapeutics
Yang, W., Cao, J., Cheng, H., Chen, L., Yu, M., Chen, Y., & Cui, X. (2022) · Bioactive Materials · doi:10.1016/j.bioactmat.2022.11.014 · Cited by 48
Barman, T. K., Singh, A. K., Bonin, J. L., Nafiz, T. N., Salmon, S. L., & Metzger, D. W. (2022) · JCI Insight · doi:10.1172/jci.insight.159422 · Cited by 37
Galati, D., Zanotta, S., Capitelli, L., & Bocchino, M. (2021) · Allergy · doi:10.1111/all.15004 · Cited by 33
Role of the Microbiome in the Pathogenesis of COVID-19
De, R., & Dutta, S. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.736397 · Cited by 38
Mahmud, M. S., Kamrujjaman, M., Adan, M. M. I. Y., Hossain, M. A., Rahman, M. M., Islam, M. S., Mohebujjaman, M., & Molla, M. M. (2021) · Infectious Disease Modelling · doi:10.1016/j.idm.2021.11.002 · Cited by 45
Impact of January 2021 curfew measures on SARS-CoV-2 B.1.1.7 circulation in France
Domenico, L. D., Sabbatini, C. E., Pullano, G., Lévy-Bruhl, D., & Colizza, V. (2021) · Eurosurveillance · doi:10.2807/1560-7917.es.2021.26.15.2100272 · Cited by 42
Raw, R. K., Kelly, C. A., Rees, J. C., Wroe, C., & Chadwick, D. (2021) · Journal of Infection · doi:10.1016/j.jinf.2021.05.035 · Cited by 41
Nanovaccines against Viral Infectious Diseases
Heng, W. T., Yew, J. S., & Poh, C. L. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14122554 · Cited by 42
Regulation of endogenous cardiomyocyte proliferation: The known unknowns
Secco, I., & Giacca, M. (2023) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2023.04.001 · Cited by 37
Sen, P., Ravichandran, N., Nune, A., Lilleker, J. B., Agarwal, V., Kardeş, S., Kim, M., Day, J. A., Milchert, M., Gheita, T. A., et al. (2022) · Rheumatology · doi:10.1093/rheumatology/keac305 · Cited by 36
Digital herd immunity and COVID-19
Bulchandani, V. B., Shivam, S., Moudgalya, S., & Sondhi, S. L. (2021) · Physical Biology · doi:10.1088/1478-3975/abf5b4 · Cited by 42
Nickel, O., Rockstroh, A., Wolf, J., Landgraf, S., Kalbitz, S., Kellner, N., Borte, M., Pietsch, C., Fertey, J., Lübbert, C., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0263861 · Cited by 35
Neerukonda, S. N., Vassell, R. A., Lusvarghi, S., Wang, R., Echegaray, F., Bentley, L., Eakin, A. E., Erlandson, K. J., Katzelnick, L. C., Weiss, C. D., et al. (2021) · Viruses · doi:10.3390/v13122485 · Cited by 31
Vaquero, S. T., de Campos‐Mata, L., Ramada, J. M., Díaz, P., Navarro‐Barriuso, J., Ribas‐Llauradó, C., Melero, N. R., Carolis, C., Cerutti, A., Gimeno, R., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.737083 · Cited by 39
Lipid Nanoparticles Enhance mRNA Delivery to the Central Nervous System Upon Intrathecal Injection
Xue, Y., Wang, C., Li, H., Du, S., Zhong, Y., Zhang, Y., Wang, S., Guo, K., Hou, X., Kang, D. D., et al. (2025) · Advanced Materials · doi:10.1002/adma.202417097 · Cited by 34
Bell’s Palsy After 24 Hours of mRNA-1273 SARS-CoV-2 Vaccine
Iftikhar, H., Noor, S. M. U., Masood, M., & Bashir, K. (2021) · Cureus · doi:10.7759/cureus.15935 · Cited by 34
COVID-19, Vaccines, and Thrombotic Events: A Narrative Review
Abrignani, M. G., Murrone, A., Luca, L. D., Roncon, L., Lenarda, A. D., Valente, S., Caldarola, P., Riccio, C., Oliva, F. G., Gulizia, M. M., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11040948 · Cited by 40
Zhang, G. F., Meng, W., Chen, L., Ding, L., Feng, J., Pérez, J., Ali, A., Sun, S., Liu, Z., Huang, Y., et al. (2022) · Journal of Medical Virology · doi:10.1002/jmv.28032 · Cited by 35
Salmanton‐García, J., Marchesi, F., da Silva, M. G., Farina, F., Dávila, J., Bilgin, Y. M., Glenthøj, A. B., Falces‐Romero, I., van Doesum, J. A., Labrador, J., et al. (2023) · EClinicalMedicine · doi:10.1016/j.eclinm.2023.101939 · Cited by 36
Corma‐Gómez, A., Fernández‐Fuertes, M., García, E., Fuentes, A. P., Gómez‐Ayerbe, C., Rivero‐Juárez, A., Domínguez, C. B., Santos, M., Viñuela, L., Palacios, R., et al. (2022) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2022.05.018 · Cited by 35
Motos, A., López-Gavín, A., Riera, J., Ceccato, A., Fernández‐Barat, L., Bermejo-Martín, J. F., Ferrer, R., de Gonzalo‐Calvo, D., Menéndez, R., Pérez-Arnal, R., et al. (2021) · European Respiratory Journal · doi:10.1183/13993003.02275-2021 · Cited by 37
Pedrazini, M. C., & da Silva, M. H. (2021) · Dermatologic Therapy · doi:10.1111/dth.15129 · Cited by 37
Long-Term Analysis of Antibodies Elicited by Sputnik V in Tucuman, Argentina
Chahla, R. E., Tomas‐Grau, R. H., Cazorla, S. I., Ploper, D., Pingitore, E. V., López, M. A., Aznar, P., Alcorta, M. E., Vélez, E. M. D. M., Stagnetto, A., et al. (2021) · The Lancet Regional Health - Americas · doi:10.1016/j.lana.2021.100123 · Cited by 42
van Vliet, V. J. E., Huynh, N., Palà, J., Patel, A., Singer, A. U., Slater, C., Chung, J., van Huizen, M., Teyra, J., Miersch, S., et al. (2022) · PLoS Pathogens · doi:10.1371/journal.ppat.1011065 · Cited by 38
Safety and immunogenicity of inactivated COVID‐19 vaccine in health care workers
Benjamanukul, S., Traiyan, S., Yorsaeng, R., Vichaiwattana, P., Sudhinaraset, N., Wanlapakorn, N., & Poovorawan, Y. (2021) · Journal of Medical Virology · doi:10.1002/jmv.27458 · Cited by 38
COVID-19 in Latin America: A Snapshot in Time and the Road Ahead
LaRotta, J., Escobar, O., Avila-Aguero, M. L., Torres, J. P., de Almeida, R. S., Morales, G. D. C., & Srivastava, A. K. (2023) · Infectious Diseases and Therapy · doi:10.1007/s40121-022-00748-z · Cited by 49
Zhang, Y.-N., Paynter, J., Sou, C., Fourfouris, T., Wang, Y., Abraham, C., Ngo, T., Zhang, Y., He, L., & Zhu, J. (2021) · Science Advances · doi:10.1126/sciadv.abj3107 · Cited by 35
Liu, Z., Xu, W., Chen, Z., Fu, W., Zhan, W., Gao, Y., Zhou, J., Zhou, Y., Wu, J., Wang, Q., et al. (2021) · Protein & Cell · doi:10.1007/s13238-021-00871-6 · Cited by 41
Strategic and Chemical Advances in Antibody–Drug Conjugates
Alradwan, I. A., Alnefaie, M. K., Fayez, N. A., Aodah, A. H., Majrashi, M. A., Alturki, M., Fallatah, M., Almughem, F. A., Tawfik, E. A., & Alshehri, A. A. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17091164 · Cited by 49
The Immune Response to SARS-CoV-2 and Variants of Concern
Torbati, E., Krause, K. L., & Ussher, J. E. (2021) · Viruses · doi:10.3390/v13101911 · Cited by 39
Alshehry, Y., Liu, X., Zhang, Y., & Zhu, G. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113617 · Cited by 39
Evaluation of adalimumab effects in managing severe cases of COVID-19: A randomized controlled trial
Fakharian, A., Barati, S., Mirenayat, M. S., Rezaei, M. S., Haseli, S., Torkaman, P., Yousefian, S., Dastan, A., Jamaati, H., & Dastan, F. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107961 · Cited by 35
The association between COVID-19 vaccination and Bell's palsy
Cirillo, N., & Doan, R. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(21)00467-9 · Cited by 42
Multifunctional Immunoadjuvants for Use in Minimalist Nucleic Acid Vaccines
Abbasi, S., & Uchida, S. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13050644 · Cited by 36
Ronk, A. J., Lloyd, N. M., Zhang, M., Atyeo, C. G., Perrett, H. R., Mire, C. E., Hastie, K. M., Sanders, R. W., Brouwer, P. J. M., Saphire, E. O., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-41376-6 · Cited by 41
Mekonnen, B. D., & Mengistu, B. A. (2022) · Clinical Epidemiology and Global Health · doi:10.1016/j.cegh.2022.101001 · Cited by 37
Non-Viral Carriers for Nucleic Acids Delivery: Fundamentals and Current Applications
Shtykalova, S., Deviatkin, D., Freund, S., Egorova, A., & Kiselev, A. (2023) · Life · doi:10.3390/life13040903 · Cited by 49
Long-term effect of SARS-CoV-2 infection on cardiovascular outcomes and all-cause mortality
Aleksova, A., Fluca, A. L., Gagno, G., Pierri, A., Padoan, L., Derin, A., Moretti, R., Noveska, E. A., Azzalini, E., D’Errico, S., et al. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.121018 · Cited by 41
Liu, J., Xu, K., Xing, M., Zhuo, Y., Guo, J., Du, M., Wang, Q. M., An, Y., Li, J., Gao, P., et al. (2021) · Cell Discovery · doi:10.1038/s41421-021-00360-4 · Cited by 35
Feghali, E. J., Zafar, M. G., Abid, S., Santoriello, D., & Mehta, S. P. (2021) · Cureus · doi:10.7759/cureus.19616 · Cited by 34
Acceptance of COVID-19 Vaccine and Associated Factors Among Pregnant Women in Saudi Arabia
Ghamri, R. A., Othman, S., Alhiniah, M., Alelyani, R., Badawi, A., & Alshahrani, A. (2022) · Patient Preference and Adherence · doi:10.2147/ppa.s357653 · Cited by 49
Surveillance of Safety of 3 Doses of COVID-19 mRNA Vaccination Using Electronic Health Records
Niesen, M. J. M., Pawlowski, C., O’Horo, J. C., Challener, D. W., Silvert, E., Donadio, G., Lenehan, P. J., Virk, A., Swift, M. D., Speicher, L. L., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.7038 · Cited by 35
An overview of lipid constituents in lipid nanoparticle mRNA delivery systems
Wu, S., Lin, L., Shi, L., & Liu, S. (2024) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1978 · Cited by 41
Maintenance and functional regulation of immune memory to COVID-19 vaccines in tissues
Davis‐Porada, J., George, A. B., Lam, N., Caron, D. P., Gray, J. I., Huang, J., Hwu, J., Wells, S. B., Matsumoto, R., Kubota, M., et al. (2024) · Immunity · doi:10.1016/j.immuni.2024.10.003 · Cited by 44
In Gratitude for mRNA Vaccines
Stuart, L. M. (2021) · New England Journal of Medicine · doi:10.1056/nejmcibr2111445 · Cited by 36
Gobeil, P., Pillet, S., Boulay, I., Séguin, A., Makarkov, A. I., Heizer, G., Bhutada, K., Mahmood, A., Charland, N., Trépanier, S., et al. (2021) · medRxiv · doi:10.1101/2021.05.14.21257248 · Cited by 33
Self-citationUse of analgesics/antipyretics in the management of symptoms associated with COVID-19 vaccination
Ooi, E. E., Dhar, A., Petruschke, R. A., Locht, C., Buchy, P., & Low, J. G. H. (2022) · npj Vaccines · doi:10.1038/s41541-022-00453-5 · Cited by 42
Selvaraj, G., Kaliamurthi, S., Peslherbe, G. H., & Wei, D. (2021) · Interdisciplinary Sciences Computational Life Sciences · doi:10.1007/s12539-021-00438-3 · Cited by 37
Metadata
- Authors
- Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., McGettigan, J., Khetan, S., Segall, N., Solis, J., Brosz, A., Fierro, C., Schwartz, H., Neuzil, K., Corey, L., Gilbert, P., Janes, H., Follmann, D., Marovich, M., Mascola, J., Polakowski, L., Ledgerwood, J., Graham, B. S., Bennett, H., Pajon, R., Knightly, C., Leav, B., Deng, W., Zhou, H., Han, S., Ivarsson, M., Miller, J., & Zaks, T.
- Affiliations
- Brigham and Women's Hospital (US)
- From Brigham and Women’s Hospital (L.R.B.), Boston, and Moderna, Cambridge (H.B., R.P., C.K., B.L., W.D., H.Z., S.H., M.I., J. Miller, T.Z.) — both in Massachusetts; Baylor College of Medicine (H.M.E.S.) and Centex Studies (J.S.) — both in Houston; Meridian Clinical Research, Savannah (B.E., S.K., A.B.), and Emory University (N.R.) and Atlanta Clinical Research Center (N.S.), Atlanta — all in Georgia; University of Maryland School of Medicine, Baltimore (K.K., K.N.), and National Institute of Allergy and Infectious Diseases, Bethesda (D.F., M.M., J. Mascola, L.P., J.L., B.S.G.) — both in Maryland; Saint Louis University School of Medicine, St. Louis (S.F.); University of Illinois, Chicago, Chicago (R.N.); George Washington University School of Medicine and Health Sciences, Washington, DC (D.D.); University of California, San Diego, San Diego (S.A.S.); Vanderbilt University School of Medicine, Nashville (C.B.C.); Quality of Life Medical and Research Center, Tucson, AZ (J. McGettigan); Johnson County Clin-Tr...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-02-04
- Volume
- 384
- Issue
- 5
- Pages
- 403-416
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7787219
- OpenAlex
- W3113734454
- Cited by
- 10,119
- References
- 24
- Citations by year
- 2026: 622 · 2025: 962 · 2024: 1186 · 2023: 1691 · 2022: 2854 · 2021: 2793
- FWCI
- 240.84
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- New England Journal of Medicine (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Digital Commons-TMC (Texas Medical Center) (submittedVersion)
- Funders
- National Institute of Allergy and Infectious Diseases (ACTG Leadership and Operations Center UM1 AI 68636, HPTN Leadership and Operations Center UM1 AI 68619, HVTN Laboratory Center UM1 AI 68618, HVTN Leadership and Operations Center UM1 AI 68614, HVTN Statistics and Data Management Center UM1 AI, IDCRC leadership group 5 UM1 AI148684-03)
- Federal funds from the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority (Contract No. 75A50120C00034)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- mRNA-1273 vaccine, SARS-CoV-2, COVID-19 vaccines, vaccine efficacy, vaccine safety, reactogenicity, adverse events, vulnerable populations, older adults, immunocompromised patients, breakthrough infection, severe COVID-19 prevention
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, 2019-nCoV Vaccine mRNA-1273, Adolescent, Adult, Aged, Female, Humans, Male, Middle Aged, Incidence, Single-Blind Method, Treatment Outcome, Young Adult, Patient Acuity, Spike Glycoprotein, Coronavirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.